Literature DB >> 26131056

Serum glycated albumin is superior to hemoglobin A1c for correlating with HMGB1 in coronary artery disease with type 2 diabetic mellitus patients.

Jianjun Yin1, Daoqun Jin2, Hong Wang1.   

Abstract

High mobility group box 1 protein (HMGB1) was significantly increased in coronary artery disease (CAD) with type 2 diabetic mellitus (T2DM) patients. This study was to investigate the relationship between average blood glucose level and HMGB1 level in CAD with T2DM patients. 164 CAD patients were divided into two groups: CAD with T2DM patients group and CAD without T2DM patients group. Glycated albumin (GA) and glycosylated hemoglobin A1c (HbA1c) and HMGB1 concentrations were measured in CAD with T2DM patients. The fasting glucose levels, GA and HbA1c levels were sinificantly increased in CAD with T2DM patients compared to those in CAD without T2DM patients (all P<0.05). The hs-CRP levels in CAD with T2DM patients were significantly higher than those in CAD without T2DM patients (P<0.05). The HMGB1 levels in CAD with T2DM patients were also significantly higher than those in CAD without T2DM patients (P<0.05). Both serum GA levels and HbA1c levels were positively correlated with HMGB1 levels (n=84, r=0.512 and r=0.402, both P<0.05). The present study showed that both serum GA levels and HbA1c levels were positively related with HMGB1 levels in CAD with T2DM patients. Increased blood glucose levels may contribute to the increased HMGB1 levels. GA level is superior to HbA1c level for correlating with HMGB1 level.

Entities:  

Keywords:  Coronary artery disease; glycated albumin; glycosylated hemoglobin A1c; high mobility group box 1 protein; type 2 diabetic mellitus

Year:  2015        PMID: 26131056      PMCID: PMC4483900     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients.

Authors:  Ying Shen; Li Jin Pu; Lin Lu; Qi Zhang; Rui Yan Zhang; Wei Feng Shen
Journal:  Cardiology       Date:  2012-09-25       Impact factor: 1.869

2.  Fluvastatin reduces the high mobility group box 1 protein expression in hyperlipidemia.

Authors:  Raluca Haraba; Elena Uyy; Viorel I Suica; Luminita Ivan; Felicia Antohe
Journal:  Int J Cardiol       Date:  2011-05-12       Impact factor: 4.164

3.  Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein.

Authors:  Raluca Haraba; Viorel I Suica; Elena Uyy; Luminita Ivan; Felicia Antohe
Journal:  Cell Tissue Res       Date:  2011-11-24       Impact factor: 5.249

4.  HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction.

Authors:  M Andrassy; H C Volz; N Riedle; G Gitsioudis; C Seidel; D Laohachewin; A R Zankl; Z Kaya; A Bierhaus; E Giannitsis; H A Katus; G Korosoglou
Journal:  J Intern Med       Date:  2011-03-28       Impact factor: 8.989

5.  The extracellular release of HMGB1 during apoptotic cell death.

Authors:  Charles W Bell; Weiwen Jiang; Charles F Reich; David S Pisetsky
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-19       Impact factor: 4.249

6.  Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats.

Authors:  Xiaorong Hu; Xiaoya Zhou; Bo He; Changwu Xu; Liu Wu; Bo Cui; Huazhi Wen; Zhibing Lu; Hong Jiang
Journal:  Eur J Pharmacol       Date:  2010-04-18       Impact factor: 4.432

7.  Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction.

Authors:  Morten V Sørensen; Sune Pedersen; Rasmus Møgelvang; Jan Skov-Jensen; Allan Flyvbjerg
Journal:  JACC Cardiovasc Interv       Date:  2011-03       Impact factor: 11.195

Review 8.  Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.

Authors:  Charles A Reasner
Journal:  J Cardiovasc Pharmacol       Date:  2008-08       Impact factor: 3.105

9.  Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines.

Authors:  N Kalinina; A Agrotis; Y Antropova; G DiVitto; P Kanellakis; G Kostolias; O Ilyinskaya; E Tararak; A Bobik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-16       Impact factor: 8.311

10.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

View more
  2 in total

1.  Serum levels of the high-mobility group box 1 protein (HMGB1) in children with type 1 diabetes mellitus: case-control study.

Authors:  Igor Marjanac; Robert Lovrić; Jerko Barbić
Journal:  Cent Eur J Immunol       Date:  2019-04-15       Impact factor: 2.085

Review 2.  High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives.

Authors:  Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Giovanni Pecorini; Raffaele Landolfi; Andrea Flex
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.